A recent meta-analysis indicated that FcRn inhibitors (e.g., efgartigimod alfa) have favorable efficacy in patients with myasthenia gravis and do not carry increased safety risks (Li et al., 2024). This evidence concerns the gene FCGRT and myasthenia gravis.